Beta Bionics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-01-16: Study NCT07011147; Company role Collaborator; Phase Not applicable; Status Recruiting.
- 2024-09-24: Study NCT06449677; Company role Collaborator; Phase Phase 3; Status Active not recruiting.
- 2024-05-01: Study NCT06891898; Company role Lead sponsor; Phase Observational; Status Recruiting.
- 2022-03-31: Study NCT05168657; Company role Collaborator; Phase Not applicable; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-01-16 | NCT07011147 Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery | Collaborator Lead: University of Colorado, Denver | Not applicable | Recruiting | Type 1 Diabetes (T1D); Type 2 Diabetes; Diabetes, Autoimmune; Diabetes Mellitus; Diabetes Mellitus Type 2; Diabetes Mellitus, Type I; Diabetes, Type II; Diabetes; Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus Type II; Diabetes Type 2 on Insulin | 240 | 2029-04-01 |
| 2024-09-24 | NCT06449677 Bionic Pancreas in CFRD | Collaborator Lead: Jaeb Center for Health Research | Phase 3 | Active not recruiting | Cystic Fibrosis-related Diabetes | 150 | 2027-05-31 |
| 2024-05-01 | NCT06891898 The iLet Experience Study | Lead sponsor | Observational | Recruiting | Type 1 Diabetes | 1,875 | 2027-06 |
| 2022-03-31 | NCT05168657 Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth | Collaborator Lead: University of Colorado, Denver | Not applicable | Completed Results posted | Diabetes Mellitus, Type 1; Type 1 Diabetes; Diabetes, Autoimmune; Diabetes type1; Autoimmune Diabetes; Diabetes Mellitus, Brittle; Diabetes Mellitus, Insulin-Dependent; Diabetes Mellitus, Insulin-Dependent, 1; Diabetes Mellitus, Juvenile-Onset; Diabetes Mellitus, Ketosis-Prone; Diabetes Mellitus, Sudden-Onset; Insulin-Dependent Diabetes Mellitus 1; Juvenile-Onset Diabetes; Type 1 Diabetes Mellitus | 54 | 2023-05-23 |
| 2021-08-26 | NCT03258853 Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes | Collaborator Lead: Massachusetts General Hospital | Not applicable | Completed Results posted | Cystic Fibrosis-related Diabetes | 22 | 2022-06-29 |
| 2021-04 | NCT04227626 Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT | Collaborator Lead: Massachusetts General Hospital | Not applicable | Withdrawn | Type 1 Diabetes; Type 2 Diabetes Treated With Insulin | 0 | 2021-04 |
| 2020-03-31 | NCT04200313 The Insulin-Only Bionic Pancreas Pivotal Trial | Collaborator Lead: Jaeb Center for Health Research | Not applicable | Completed Results posted | Diabetes Mellitus; Type 1 Diabetes; Diabetes Mellitus, Type 1 | 440 | 2022-01-14 |
| 2019-05-15 | NCT03840278 The Bihormonal iLet Bionic Pancreas Feasibility Study | Collaborator Lead: Massachusetts General Hospital | Phase 2, Phase 3 | Completed Results posted | Type 1 Diabetes Mellitus | 12 | 2019-07-03 |
| 2016-11 | NCT02971228 Feasibility Trial Testing the Bionic Pancreas With ZP4207 | Collaborator Lead: Zealand Pharma | Phase 2 | Completed Results posted | Diabetes Mellitus, Type 1 | 13 | 2017-06-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |